1. Sulfonamide-chalcone hybrid compound suppresses cellular adhesion and migration: Experimental and computational insight.
- Author
-
Araújo GS, Moura AF, Barros AB, Moraes MO, Pessoa C, Perez CN, Castro MRC, Ribeiro FOS, Silva DAD, Sousa PSA, Rocha JA, Marinho Filho JDB, and Araujo AJ
- Subjects
- Mice, Animals, Cell Line, Tumor, Matrix Metalloproteinase 2 metabolism, Melanoma, Experimental pathology, Melanoma, Experimental drug therapy, Melanoma, Experimental metabolism, Microscopy, Atomic Force, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Chalcones pharmacology, Chalcones chemistry, Humans, Cell Movement drug effects, Cell Adhesion drug effects, Sulfonamides pharmacology, Sulfonamides chemistry, Molecular Docking Simulation, Chalcone pharmacology, Chalcone chemistry, Chalcone analogs & derivatives
- Abstract
In the present study, the effect of sulfonamide-chalcone 185 (SSC185) was investigated against B16-F10 metastatic melanoma cells aggressive actions, besides migration and adhesion processes, by in silico and in vitro assays. In silico studies were used to characterize the pharmacokinetic profile and possible targets of SSC185, using the pkCSM web server, and docking simulations with AutoDock Tools. Furthermore, the antimetastatic effect of SSC185 was investigated by in vitro experiments using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide), colony, scratch, and cell adhesion assays, and atomic force microscopy (AFM). The molecular docking results show better affinity of SSC185 with the metalloproteinases-2 (MMP-2) and α5β1 integrin. SSC185 effectively restricts the formation of colonies, migration, and adhesion of B16-F10 metastatic melanoma cells. Through the AFM images changes in cells morphology was identified, with a decrease in the filopodia and increase in the average cellular roughness. The results obtained demonstrate the potential of this molecule in inhibit the primordial steps for metastasis, which is responsible for a worse prognosis of late stage cancer, being the main cause of morbidity among cancer patients., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF